Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2023-11-20 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2023-11-20 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a material definitive agreement related to a securities purchase agreement and a registered direct offering, including details about the issuance of shares and warrants, placement agent fees, and lock-up agreements. It also discusses compliance with NYSE American listing standards and includes a press release as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is primarily an announcement of a financing transaction and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-11-17 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying base prospectus filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common stock and unregistered warrants by MAIA Biotechnology, Inc., including terms of the offering, use of proceeds, risk factors, and plan of distribution. This type of document is a capital raising disclosure related to financing activities, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication or a regulatory filing certification. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, consistent with a financing update rather than a brief announcement or other filing type.
2023-11-17 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, by MAIA Biotechnology, Inc. It reports the issuance of a warrant to purchase common stock, details about the warrant terms, vesting, and related financial advisory fees. The filing is a current report disclosing a material definitive agreement and unregistered sales of equity securities. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The content focuses on capital raising and financing activities through the issuance of warrants and related terms. Therefore, the document fits the Capital/Financing Update category (CAP).
2023-11-16 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes termination of a material definitive agreement (the Sales Agreement), appointment and departure of key officers, and a notice of potential delisting due to non-compliance with listing standards. These are typical disclosures for a Form 8-K. The document does not contain full financial statements or detailed financial analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release or Proxy Solicitation. The primary focus is on management changes and termination of agreements, which aligns with Board/Management Information (MANG). Therefore, the best classification is MANG with high confidence.
2023-11-15 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a registration statement on Form S-3. It discusses amendments to a previous prospectus supplement and the termination of a sales agreement for an at-the-market offering of common stock. The content focuses on capital raising activities and updates regarding the offering and sales agreement termination. It does not contain financial statements or detailed financial performance data, so it is not an Annual Report, Interim Report, or Earnings Release. It is clearly related to financing activities and capital structure changes. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is under 5,000 characters and is a detailed supplement, not just an announcement, so it is not a Report Publication Announcement (RPA).
2023-11-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.